257 related articles for article (PubMed ID: 29521655)
21. Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome.
Hascoët S; Baruteau AE; Humbert M; Simonneau G; Jais X; Petit J; Laux D; Sitbon O; Lambert V; Capderou A
J Heart Lung Transplant; 2017 Apr; 36(4):386-398. PubMed ID: 27866929
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of selexipag for treatment of pulmonary arterial hypertension in an Asian population.
Loo G; Yap J; Hon JS; Ismail A; Ruan W; Low A; Lim ST; Tan JL
Ann Acad Med Singap; 2023 Apr; 52(4):219-221. PubMed ID: 38904536
[No Abstract] [Full Text] [Related]
23. Selexipag: First Global Approval.
Scott LJ
Drugs; 2016 Mar; 76(3):413-8. PubMed ID: 26846322
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary arterial hypertension: a current review of pharmacological management.
Sahni S; Ojrzanowski M; Majewski S; Talwar A
Pneumonol Alergol Pol; 2016; 84(1):47-61. PubMed ID: 26693827
[TBL] [Abstract][Full Text] [Related]
25. Idiopathic Pulmonary Arterial Hypertension: Evolving Therapeutic Strategies.
Kanwar M; Raina A; Passineau M; Benza R
Semin Respir Crit Care Med; 2017 Oct; 38(5):606-618. PubMed ID: 29032564
[No Abstract] [Full Text] [Related]
26. Selexipag use for paediatric pulmonary hypertension: a single centre report focussed on congenital heart disease patients.
Lafuente-Romero A; Rodriguez Ogando A
Cardiol Young; 2021 Sep; 31(9):1513-1515. PubMed ID: 33781364
[TBL] [Abstract][Full Text] [Related]
27. [Eisenmenger syndrome. Specific treatments].
Acar P
Presse Med; 2009 Dec; 38 Suppl 1():1S18-22. PubMed ID: 20141997
[No Abstract] [Full Text] [Related]
28. A Contemporary Approach to Pulmonary Arterial Hypertension.
Krishnan U; Horn EM
Curr Atheroscler Rep; 2016 Sep; 18(9):58. PubMed ID: 27491673
[TBL] [Abstract][Full Text] [Related]
29. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
[TBL] [Abstract][Full Text] [Related]
30. Baseline history of patients using selexipag for pulmonary arterial hypertension.
Highland KB; Hull M; Pruett J; Elliott C; Tsang Y; Drake W
Ther Adv Respir Dis; 2019; 13():1753466619843774. PubMed ID: 30983530
[TBL] [Abstract][Full Text] [Related]
31. Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O; Channick R; Chin KM; Frey A; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; Preiss R; Rubin LJ; Di Scala L; Tapson V; Adzerikho I; Liu J; Moiseeva O; Zeng X; Simonneau G; McLaughlin VV;
N Engl J Med; 2015 Dec; 373(26):2522-33. PubMed ID: 26699168
[TBL] [Abstract][Full Text] [Related]
32. Pathways in pulmonary arterial hypertension: the future is here.
Sitbon O; Morrell N
Eur Respir Rev; 2012 Dec; 21(126):321-7. PubMed ID: 23204120
[TBL] [Abstract][Full Text] [Related]
33. Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
Hardin EA; Chin KM
Drug Des Devel Ther; 2016; 10():3747-3754. PubMed ID: 27895464
[TBL] [Abstract][Full Text] [Related]
34. An evaluation of selexipag for the treatment of pulmonary hypertension.
Panagiotidou E; Boutou A; Pitsiou G
Expert Opin Pharmacother; 2021 Jan; 22(1):29-36. PubMed ID: 32867545
[TBL] [Abstract][Full Text] [Related]
35. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.
Mehta PK; Simpson L; Lee EK; Lyle TA; McConnell ME; Book WM
Tex Heart Inst J; 2008; 35(3):256-61. PubMed ID: 18941642
[TBL] [Abstract][Full Text] [Related]
36. Oral treprostinil in the treatment of pulmonary arterial hypertension.
Feldman J; Habib N; Radosevich J; Dutt M
Expert Opin Pharmacother; 2017 Oct; 18(15):1661-1667. PubMed ID: 28922964
[TBL] [Abstract][Full Text] [Related]
37. [Current issues in pulmonary hypertension].
Forster T
Orv Hetil; 2012 Apr; 153(16):603-6. PubMed ID: 22510315
[TBL] [Abstract][Full Text] [Related]
38. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636
[TBL] [Abstract][Full Text] [Related]
39. Update on pharmacotherapy for pulmonary hypertension.
Prior DL; Adams H; Williams TJ
Med J Aust; 2016 Sep; 205(6):271-6. PubMed ID: 27627939
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
